Considerable controversy surrounds the cost-effectiveness of screening and surveillance for Barrett esophagus (BE) as well as the role of ablative therapies aimed at decreasing the related esophageal adenocarcinoma (EAC) risk. The ACG has evaluated the most current published clinical reports on this topic and now offers evidence-based, weighted recommendations on current best practice – See more at:
http://www.jwatch.org/na39969/2015/12/18/barrett-esophagus-updated-guideline-recommendations
Barrett Esophagus: Updated Guideline Recommendations